Back to Parkinsons Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT05508867

NCT05508867
Completed Phase 2 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with classical Hodgkin lymphoma (a specific type of blood cancer), confirmed by a tissue biopsy, that shows up on a specific type of PET scan (FDG-PET).
  • Your lymphoma has either come back after treatment or never fully responded to treatment, and you have run out of standard treatment options that are known to help.
  • Your cancer continued to grow or spread while you were being treated with a type of immunotherapy drug called an anti-PD-(L)1 antibody (such as pembrolizumab or nivolumab), either alone or combined with other treatments.
  • You are able to provide a tumor tissue sample — either one taken within the last 5 years or a newly collected one — that has not been treated with radiation.

Who may not be able to join:

  • You have a condition that weakens your immune system, or you are currently taking steroids or other medicines that suppress your immune system on an ongoing basis.
  • Your cancer has spread to your brain or spinal cord, or you have had this in the past.
  • You have an autoimmune disease (where the body attacks itself) that needed medical treatment within the last 2 years, not including simple hormone replacement therapy.
  • You have had lung inflammation (pneumonitis) or scarring of the lungs (interstitial lung disease) in the past that required steroid treatment, or you currently have this condition.
  • You currently have an infection that requires treatment with medicines.
  • You have a history of a rare and serious immune condition called hemophagocytic lymphohistiocytosis (confirm with trial site).
  • You have a seizure disorder that is not well controlled with medication.
  • You have a significant or active heart or blood vessel condition.
  • You have received any cancer treatment, including experimental treatments, within the 4 weeks before joining the trial.
  • You have received radiation therapy within 2 weeks before starting the trial, or you are still experiencing side effects from radiation that require steroid treatment.
  • You have recently had a major surgery and have not yet fully recovered.
  • You have another cancer that is still being treated or has required active treatment within the past 3 years.
  • You have a history of HIV infection.
  • You have received a donor stem cell transplant or an organ transplant within the last 5 years.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Merck Sharp & Dohme LLC
Registry
clinicaltrials_gov
Start date
18 October 2022
Est. completion
3 September 2025

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇨🇱 Chile 🇨🇳 China 🇨🇿 Czechia 🇫🇷 France 🇩🇪 Germany 🇮🇱 Israel 🇲🇽 Mexico 🇵🇱 Poland 🇰🇷 South Korea 🇪🇸 Spain 🇸🇪 Sweden 🇨🇭 Switzerland Turkey (Türkiye) 🇬🇧 United Kingdom 🇺🇸 United States

4 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Progression Free Survival (PFS) per Lugano Response Criteria as Assessed by investigator

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov